5759 Results for “Low-cost prescriptions https://simplemedrx.top">”

Widespread criticism of elites and their ‘experts ’ raises questions about how economists should perceive their role, and what role societies should give them. We invited four scholars to start an online conversation by sharing their perspectives 

A new INET Working Paper by Yaroslav Melekh, James Dixon, Katrina Salmon, and Michael Grubb, interrogates the contradictions between fossil lock-in through LNG import capacity and overcontracting, and policy-driven demand reduction. Here is a summary of the paper’s main findings.

Many indicators say the US is close to full employment: Hours of work tell a different story.

Growing income inequality is threatening the American middle class, and the middle class is vanishing before our eyes. We are still one country, but the stretch of incomes is fraying the unity of our nation.

Mott walks us through answers many careful readers of Kalecki, Keynes, Steindl, and Minsky knew all along.

The soaring costs of city life appear to be sending urban voters toward progressive leaders who promise relief, both in the U.S. and globally.

Evidence-based answers to the main (policy) questions concerning the return of high inflation

Hoping to learn from other countries’ experiences in organizing finance for agriculture, more than 150 Americans were sent abroad in the summer of 1913 to investigate the minutiae of farm-credit systems in and around Europe.

Misaligned incentives account for many of the most troubling features of the pharmaceutical industry’s present practices and performance.

Lance Taylor’s New INET Paper

In a new book from Cambridge University Press, Lance Taylor reveals that wage repression — far more than monopoly power, offshoring or technological change — is driving rising inequality.

This research project studies the macroeconomic effects of rising inequality by focusing not on top incomes but instead on the economics of the “bottom 99%” which has been squeezed out by rising inequality and falling labor shares.

Why Pushing on a String Has Never Worked

Gilead’s shareholders want exorbitant profits from Remdesivir, even though it was the public that enabled its development.

In this interview, Camilla Toulmin and Folashadé Soulé speak with Carlos Lopes, Professor at the Nelson Mandela School of Public Governance, University of Cape Town, Visiting Professor at Sciences Po, Paris and an Associate Fellow at Chatham House, London